Background: Various risk stratification systems for acute non-ST segment elevation myocardial infarction (NSTEMI) were proposed to date. Among them, TIMI risk scoring system had proven efficacy as bed side risk assessment modality. And biomarkers have emerged as interesting predictors of this risk. The aim of this study was to identify the usefulness of the multiple biomarker approach including troponin I (TnI), C-reactive protein (CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP) as predictors of adverse event. Methods: We included 1621 patients with NSTEMI in Korea acute MI registry (KAMIR). Baseline measurements for TnI, CRP, and NT-proBNP were performed. A positive biomarker test was considered as the levels were upper than the 75th percentile of our population. The risk for major adverse cardiac events (MACE) at 6 months follow-up was analysed. Results: 88 patients (9.5 %) had MACE at 6-month follow-up. In multivariate analysis, NT pro-BNP was the predictor of adverse events [hazards ratio (HR): 2.85 (1.30–2.04), P < 0.001] but elevated CRP and TnI was not independent predictor of MACE. After adjusting for baseline characteristics, biomarker scoring that indicate the number of individual positive biomarker, from one to three point was associated with adverse events at 6 months [HR 4.09 (95%CI 1.21–3.54), P < 0.001]. When the patients were divided by risk groups according to the Thrombolysis in Myocardial Infarction (TIMI) risk score, patients with two or three elevated biomarkers had higher risk score (P = 0.004). Conclusions: Biomarker scoring system using multi-marker approach based on TnI, CRP, and NT-proBNP was valuable method to predict the MACE in patient with NSTEMI and can provide additional clinical information to TIMI risk score system.